Normally present at very low levels in plasma, antibodies of the immunoglobulin E (IgE) isotype were first discovered in 1967, decades after the description of IgA, IgG, and IM. IgE antibodies are produced primarily by plasma cells in mucosal-associated lymphoid tissue and their levels are uniformly elevated in patients suffering from atopic conditions like allergic rhinitis, asthma and atopic dermatitis. Production of allergen-specific IgE in atopic individuals is driven both by a genetic predisposition to the synthesis of this isotype as well as by environmental factors, including chronic allergen exposure. (more…)
The precise mechanisms underlying the effects of Specific Immunotherapy are not well understood but several studies have shown ...
Our current knowledge for trigger factor and food allergy intolerance is still in it infancy level. We already known that the aller ...
Treatment with omalizumab has been shown to reduce serum free IgE concentrations and to have beneficial effects on allergic airway ...
A paradigm of immune development underlies allergy development and progression in early childhood. Briefly, the immune system o ...
IgE plays an important role in allergic asthma. Reducing IgE in the airway mucosa should reduce airway inflammation. Omalizumab has ...
Tumour necrosis factor alpha (TNF-a) is a major therapeutic target in a range of chronic inflammatory disorders involving neutrophils and its excess production is characterized by a Th1-type immune response. Asthma is regarded as a Th2-type disorder when associated with atopy, (more…)
Tumour Necrosis Factor is a pro-inflammatory cytokine implicated in the pathogenesis of asthmatic airway inflammation, hyper-react ...
Roflumilast is an oral, once-daily inhibitor of phosphodiesterase type 4 (PDE4) that prevents the breakdown of cyclic adenosine ...
IgE plays an important role in allergic asthma. Reducing IgE in the airway mucosa should reduce airway inflammation. Omalizumab has ...
Lidocaine is a local anaesthetic that possesses the ability to potently shorten eosinophil survival. This study assessed the sa ...
An emerging concept is that pro-inflammatory signals lead to loss of Regulatory T Cells (Treg) function. Pasare and Medzhitov ( ...
Allergic rhinitis is a high-prevalence disease. This high prevalence translates into a high cost to society in terms of overall healthcare utilization, and also a high cost in terms of the quality of life of those who suffer from moderate or severe disease.
Allergic rhinitis has traditionally been divided into seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). This classification is helpful in indicating the season of maximum symptoms and the likely causative allergens immunotherapy. (more…)
About twenty percent of patients who have common allergic rhinitis are also having perennial allergic rhinitis symptoms. This f ...
Asthmatic children who also have Allergic Rhinitis seem to have higher morbidity and to use more healthcare resources. This was fur ...
Allergic rhinitis or nasal allergy is a serious disease, but has huge implications for society. A survey of Latin America and that ...
Specific immunotherapy has been widely used to treat allergic rhinitis symptoms. As with any other form of specific immunotherapy, ...
Allergen-specific immunotherapy aims to correct the underlying immune imbalance associated with specific immunotherapy allergic rhi ...
Treatment with omalizumab has been shown to reduce serum free IgE concentrations and to have beneficial effects on allergic airway disease. However, its effect on local IgE synthesis is unknown. The authors investigated whether omalizumab therapy diminishes nasal reactivity to allergen and local IgE production. Nineteen patients with perennial allergic rhinitis were treated with intravenous omalizumab every 2 weeks for 26 weeks in an open-label study. (more…)
IgE plays an important role in allergic asthma. Reducing IgE in the airway mucosa should reduce airway inflammation. Omalizumab has ...
Anti-IgE therapy could be particularly beneficial for patients with concomitant asthma and rhinitis as it targets a common fact ...
Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 ther ...
After nasal allergen challenge, substance P and CGRP are released into nasal secretions of atopic patients . In allergic rhinit ...
Non-allergic rhinitis is defined by the absence of positive SPTs or radioallergosorbent test (RAST) to common allergens. Ideall ...